Overview
Nucleai provides AI-powered spatial biomarker and diagnostics solutions for biopharma, analyzing cellular interactions in tissue samples to advance drug development in oncology. Their platform uses deep learning for multiplex immunofluorescence analysis, automating normalization of high-plex imaging data to identify biomarkers for ADCs, bispecifics, immunotherapy, NSCLC, and melanoma. It enables precise prediction of treatment responses and scalable validation across cohorts.
Frequently asked questions
- What are Nucleai's key capabilities in spatial biology?
- Nucleai leverages AI and geospatial methods to analyze multiplex immunofluorescence imaging, mapping cellular interactions and protein expression for biomarker discovery in oncology therapeutics like ADCs and immunotherapies.
- What therapeutic areas does Nucleai support?
- Nucleai focuses on precision oncology, providing spatial biomarkers for NSCLC, melanoma, ADCs, bispecific antibodies, and immunotherapy response prediction.
- Where is Nucleai headquartered and what is their geographical focus?
- Nucleai is headquartered in Tel Aviv, Israel, and serves global biopharma clients through AI-driven spatial analysis platforms applicable worldwide.